HUMAN CANCER CELL PANEL
Facilitating novel anti-cancer drug discovery.
Human cancer cell panels have long been a valuable tool in anti-cancer drug discovery: they assess the potential cytotoxicity and growth-inhibition effects of the tested compounds against different types of tumors. Human cancer cell panels are not devoid of limitations, but they remain a far-reaching tool in oncology and immuno-oncology.
At PharmaLegacy, we provide our clients with more than 60 human cancer cells (screenable by our cell proliferation/cytotoxicity assay), covering liver, lung, breast, lymphoma, colon, melanoma, leukemia and myeloma tumors. Contact us now for more information on our human cancer cell panel.
MODELS / SERVICES
Further In Vivo Study:
The capability to succeed:
- AAALAC accredited vivarium
- Research data electronically managed by BioBook (IDBS, UK)
- 600+ validated animal models of disease spanning 40+ diseases
- PK/PD, molecular pharmacology and preliminary toxicology adjacency studies
Seeking uncompromising quality with deep skills and knowledge? Contact PharmaLegacy.
Providing Better Data for Critical Immuno-Oncology Pipeline Decisions
PharmaLegacy works to get you the answers you need with our wide selection of carefully developed in vivo and in vitro models. In this document, you’ll see a sample of the in vitro assays we run along with a sample of real-world data from them. See why over 700 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical pipeline decisions.